EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with pancreatobiliary subtype ampullary adenocarcinoma

Jiahao Xue iD, Xinjun Lu, Xiangde Shi, Kenglong Huang, Yanfang Ye, Qibin Tang, Xianhuan Yu, Chao Liu

The Oncologist · 04.06.2025 · 30 (6)

DOI: 10.1093/oncolo/oyaf104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.06.2025. Verfasst von Jiahao Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memo…. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Ampulla of Vater, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangzhou Science and Technology Foundation, Fundamental Research Funds for the Central Universities, Sun Yat-sen University, Guangzhou Key Laboratory of Precise Diagnosis and Treatment of Biliary Tract Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and safety of chemotherapy combined with programmed cell death protein-1 (PD-1) inhibitors in postoperative adjuvant therapy of pancreatobiliary subtype ampullary adenocarcinoma (AAC) are uncertain. This study aims to evaluate the effect of such treatment on the survival of this patient population.

Methods

We retrospectively collected patients with pancreatobiliary subtype AAC who underwent surgical treatment at the Sun Yat-sen Memorial Hospital from January 2018 to December 2022. Patients with high-risk recurrence factors after surgery were divided into surgery alone group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy group. The Kaplan–Meier method was used to plot survival curves, and the Log-Rank method was used to compare the differences in overall survival (OS) and recurrence-free survival (RFS) between groups.

Results

A total of 71 people were enrolled, including 24 patients received surgery alone, 31 patients received adjuvant chemotherapy, and 16 patients received adjuvant chemoimmunotherapy. The median time of clinical follow-up was 17.8 [IQR 8.3-28.4] months. The 1-year OS rates of the surgery alone group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy were 41.7%, 71.0%, and 93.3%, respectively. The 2-year OS rates were 28.6%, 47.7%, and 84.0%, respectively. The median OS was 6.8 months and 22.1 months, but the adjuvant chemoimmunotherapy group did not reach (P = .0002). The median RFS was 4.7 months, 15.7 months, and 14.8 months, respectively, but the differences were not statistically significant (P = .0613). Univariate and multivariate Cox analysis results showed that tumor size >2.3 cm (HR = 2.06, 95% CI, 1.06-4.04; P = .034) and the treatment regimen were independent factors affecting prognosis, compared to surgery alone and adjuvant chemotherapy (HR = 0.521, 95% CI, 0.26-1.04; P = .065), adjuvant chemoimmunotherapy (HR = 0.106, 95% CI, 0.02-0.47; P = .003) significantly improves patient survival. There was no statistically significant difference in any complications between the 3 groups (P > .05). Compared with the adjuvant chemotherapy group, patients in the adjuvant chemoimmunotherapy group are more likely to experience hypothyroidism (P = .044) and pruritus (P = .022). There is no statistically significant difference in other AEs between the 2 groups (P > .05).

Conclusion

Compared with surgery alone or adjuvant chemotherapy, patients with pancreatobiliary subtype AAC who received adjuvant chemoimmunotherapy showed better OS, and the drug-related toxicity was acceptable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaPancreatic NeoplasmsAmpulla of VaterImmunotherapyHumansMaleFemaleChemotherapy, AdjuvantRetrospective StudiesMiddle AgedAged

Stichwörter der Autor:innen

adjuvant therapychemoimmunotherapyhigh risk of recurrencepancreatobiliary subtype ampullary adenocarcinomaprognosis

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
  • Clinical Research Design Division, Sun Yat-sen Memorial Hospital, Guangzhou 510120, China.

ORCID-Profile: Jiahao Xue

Förderung

  • Guangzhou Science and Technology Foundation
  • Fundamental Research Funds for the Central Universities, Sun Yat-sen University
  • Guangzhou Key Laboratory of Precise Diagnosis and Treatment of Biliary Tract Cancer
  • Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology
  • Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes
  • Guangdong Science and Technology Department

Zitieren

APA

Xue, J., Lu, X., Shi, X., Huang, K., Ye, Y., Tang, Q., Yu, X., & Liu, C. (2025). Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with pancreatobiliary subtype ampullary adenocarcinoma. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf104

Vancouver

Xue J, Lu X, Shi X, Huang K, Ye Y, Tang Q, et al. Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with pancreatobiliary subtype ampullary adenocarcinoma. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf104

BibTeX
@article{Xue2025,
  author = {Xue, Jiahao and Lu, Xinjun and Shi, Xiangde and Huang, Kenglong and Ye, Yanfang and Tang, Qibin and Yu, Xianhuan and Liu, Chao},
  title = {Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with pancreatobiliary subtype ampullary adenocarcinoma},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {6},
  doi = {10.1093/oncolo/oyaf104}
}
Kostenlos starten →